NATCOPHARM - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 4.2
| Stock Code | NATCOPHARM | Market Cap | 19,962 Cr. | Current Price | 1,115 ₹ | High / Low | 1,135 ₹ |
| Stock P/E | 13.3 | Book Value | 462 ₹ | Dividend Yield | 0.54 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,018 ₹ | DMA 200 | 947 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 63.5 | MACD | 27.7 | Volume | 9,67,903 | Avg Vol 1Wk | 6,34,553 |
| Low price | 752 ₹ | High price | 1,135 ₹ | PEG Ratio | 0.09 | Debt to equity | 0.03 |
| 52w Index | 94.7 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 30.2 |
NATCOPHARM shows strong potential for swing trading. The RSI (63.5) and MACD (27.7) indicate bullish momentum. The current price (₹1,115) is above both the 50 DMA (₹1,018) and 200 DMA (₹947), confirming an uptrend. Fundamentals are solid with ROCE (31.8%), ROE (27.5%), and very low debt-to-equity (0.03). However, the sharp decline in quarterly PAT (₹107 Cr vs ₹501 Cr) raises caution.
✅ Optimal Entry Price: Around ₹1,080–1,100, near short-term support.
📤 Exit Strategy: If already holding, consider profit booking near ₹1,150–1,170, or exit if price falls below ₹1,050 support.
🌟 Positive
- Strong ROCE (31.8%) and ROE (27.5%) highlight efficient capital use.
- PEG ratio of 0.09 suggests undervaluation relative to growth.
- Low debt-to-equity ratio (0.03) ensures financial stability.
- FII holding increased (+2.21%), showing foreign investor confidence.
⚠️ Limitation
- Quarterly PAT dropped significantly (₹107 Cr vs ₹501 Cr).
- Dividend yield is modest at 0.54%.
- Stock trading close to 52-week high (₹1,135) may limit upside.
📰 Company Negative News
- Sharp decline in quarterly profit (-14.4% variation) raises concerns about earnings consistency.
📈 Company Positive News
- Strong fundamentals with high ROCE and ROE.
- Healthy trading volumes (9.6 lakh vs avg 6.3 lakh) indicate active participation.
🏭 Industry
- Industry P/E at 30.2 shows NATCOPHARM trades at a discount (P/E 13.3).
- Pharmaceutical sector remains resilient, supported by global healthcare demand.
✅ Conclusion
NATCOPHARM is a strong candidate for swing trading with entry near ₹1,080–1,100 and exit around ₹1,150–1,170. Attractive valuation and strong fundamentals support upside potential, but recent profit decline requires cautious monitoring. Suitable for traders seeking short-term gains with disciplined stop-loss management.